{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T18:46:08Z","timestamp":1709232368842},"reference-count":0,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,11,14]],"date-time":"2003-11-14T00:00:00Z","timestamp":1068768000000},"content-version":"vor","delay-in-days":2327,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1997,7]]},"abstract":"<jats:p> <jats:italic>Background<\/jats:italic>: Combined treatment using an acid\u2010inhibiting drug with antibiotics can cure <jats:italic>Helicobacter pylori<\/jats:italic> infection. However, eradication rates are highly variable, especially if a proton pump inhibitor is used with amoxycillin. Therefore it is important to define factors\/predictors of the clinical outcome.<\/jats:p><jats:p> <jats:italic>Methods<\/jats:italic>: In a single\u2010blind study, 60 <jats:italic>H. pylori<\/jats:italic>\u2010positive patients prospectively matched for diagnosis (erosive gastritis, duodenal and gastric ulcer), age (above and below 50 years) and smoking habits were randomly treated (each group <jats:italic>n<\/jats:italic>\u2003=\u200320) for 2 weeks with amoxycillin (1\u2003mg b.d.) and either omeprazole (20\u2003mg b.d.), lansoprazole (30\u2003mg b.d.) or ranitidine (300\u2003mg b.d.). Intragastric pH\u2003and plasma levels of the administered drugs were monitored over a dosing interval of 12\u2003h.<\/jats:p><jats:p> <jats:italic>Results<\/jats:italic>: The overall eradication rates were 45% (intention\u2010to\u2010treat, ITT, 27\/60) or 47% (per protocol 27\/58); they did not differ (ITT) between omeprazole (50%), lansoprazole (40%) and ranitidine (45%). Median pH\u2003and time at which intragastric pH\u2003was above 4 was slightly lower for ranitidine (4.0\u2003\u00b1\u20031.7; 51\u2003\u00b1\u200325%) than for omeprazole (5.4\u2003\u00b1\u20031.1; 77\u2003\u00b1\u200325%; <jats:italic>P\u2003<\/jats:italic>&lt;\u20030.05) or lansoprazole (4.4\u2003\u00b1\u20031.6; 68\u2003\u00b1\u200332%). Plasma concentrations of amoxycillin were comparable in all three treatment groups. Post\u2010treatment <jats:italic>H. pylori <\/jats:italic>status was not dependent on those levels, or the drug\u2010induced extent or duration of increased intragastric pH. However, <jats:italic>H. pylori<\/jats:italic>\u2010eradicated patients were significantly (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.05) older (56\u2003\u00b1\u200313 years) than patients still <jats:italic>H. pylori<\/jats:italic>\u2010positive (47\u2003\u00b1\u200314 years). In addition, in patients older than 50 years (<jats:italic>n<\/jats:italic>\u2003=\u200333), eradication was higher (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.01) than in patients (<jats:italic>n<\/jats:italic>\u2003=\u200325) below 50 years (65 vs. 24%). Eradication rate was highest (75\u201383%) in subgroups of patients (&gt;50 years and history of peptic ulcer or smokers). Neither activity\/grade of peptic ulcer or erosive gastritis nor initial diagnosis were predictors for clinical outcome.<\/jats:p><jats:p> <jats:italic>Conclusion<\/jats:italic>: The age of patients must be regarded as a major determinant of <jats:italic>H. pylori <\/jats:italic>eradication rate and may represent an important factor contributing to the highly variable clinical results.<\/jats:p>","DOI":"10.1046\/j.1365-2036.1997.00210.x","type":"journal-article","created":{"date-parts":[[2003,11,14]],"date-time":"2003-11-14T11:43:13Z","timestamp":1068810193000},"page":"711-718","source":"Crossref","is-referenced-by-count":19,"title":["Age\u2010dependent eradication of <i>Helicobacter pylori<\/i> with dual therapy"],"prefix":"10.1111","volume":"11","author":[{"given":"G.","family":"TREIBER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"AMMON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"KLOTZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,11,14]]},"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1997.00210.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1997.00210.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T03:17:06Z","timestamp":1694402226000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1997.00210.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["10.1046\/j.1365-2036.1997.00210.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1997.00210.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,7]]}}}